Science Corporation has successfully implanted its proprietary vision-restoring chip, PRIMA, into the first patient diagnosed with Stargardt disease. This significant advancement marks a new frontier in treating the inherited eye condition that progressively diminishes central vision.

Max Hodak, CEO of Science Corporation and former president and co-founder of Neuralink, revealed the development, emphasizing how the PRIMA implant aligns with the company’s broader ambitions in brain-computer interface (BCI) technology. Hodak articulated that the retina is an integral part of the central nervous system, positioning retinal prostheses and similar devices as forms of BCIs. This perspective broadens the scope of BCI applications beyond mere computer control to encompass a wide array of medical interventions.

The PRIMA device is already commercially available in Europe for individuals suffering from geographic atrophy, a severe form of age-related macular degeneration. Science Corporation is optimistic about extending this technology’s benefits to other conditions, including Stargardt disease, which currently lacks a cure. Stargardt disease affects the light-sensing cells in the outer retina, leading to a gradual loss of central vision for approximately 150,000 people globally.

The initial Stargardt patient received the PRIMA implant in May during a trial at Sydney Eye Hospital in Australia. Early rehabilitation sessions have shown promising results, with the patient reportedly seeing a letter during the first session and reading a word during the second. The procedure involves implanting a small chip at the back of the eye, where photoreceptor degeneration has occurred, and is complemented by camera-equipped glasses that transmit visual data to the implant, effectively acting as artificial photoreceptors.

Hodak described the current implant as a two-millimeter by two-millimeter device that provides a sharp, high-contrast, black-and-white view within a limited field of vision, enabling the perception of a few letters at a time. The company is actively developing a next-generation implant with a larger field of view and finer electrode detail, aiming to approach native visual acuity within the next five years. Science Corporation, founded in 2021, initially focused on advanced neural engineering and BCIs, but is strategically prioritizing vision restoration as a means to validate its technology and establish a sustainable business model.

Key Takeaways

• Science Corporation has implanted its PRIMA vision-restoring chip in its first Stargardt disease patient.
• The PRIMA device functions as artificial photoreceptors, aiding vision restoration for degenerative eye conditions.
• The company aims to expand BCI applications beyond vision restoration to other neurological conditions and enhance healthspan.

Editor’s Analysis & Impact

The successful implantation of the PRIMA chip in a Stargardt disease patient represents a significant stride in neurotechnology and ophthalmology. By leveraging BCI principles for vision restoration, Science Corporation is not only addressing a critical unmet medical need but also validating its core technology for broader applications. The company’s strategic focus on developing a sustainable business through medical devices before tackling more complex BCI challenges is a pragmatic approach. This development could pave the way for future treatments for a range of neurodegenerative diseases and sensory impairments, potentially redefining the boundaries of human healthspan and cognitive augmentation.

Frequently Asked Questions

Q: What is Stargardt disease?
A: Stargardt disease is an inherited eye condition that causes progressive loss of central vision due to the deterioration of photoreceptor cells in the retina.

Q: How does the PRIMA chip work?
A: The PRIMA chip acts as artificial photoreceptors. It is implanted in the eye and receives visual information from a camera-equipped headset, transmitting signals to the brain to restore a sense of vision.

Q: What are Science Corporation's future plans for BCI technology?
A: Beyond vision restoration, Science Corporation aims to develop BCIs for treating other neurological conditions, such as monitoring brain tumors or aiding recovery from strokes, with a long-term vision of understanding and engineering the brain.